Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study

References

• Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379–90.
   PubMed Web of Science ®Google Scholar
• de Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: consensus and controversies. Eur J Clin Invest 2018;48:e12913.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.
   PubMed Web of Science ®Google Scholar
• Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;75:16–22.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–18.
   PubMed Web of Science ®Google Scholar
• Fernandez-Espartero C, de Miguel E, Loza E, Tomero E, Gobbo M, Descalzo MA, et al. Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. Ann Rheum Dis 2014;73:1350–5.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009;60:717–27.
   PubMed Web of Science ®Google Scholar
• Marona J, Sepriano A, Rodrigues-Manica S, Pimentel-Santos F, Mourao AF, Gouveia N, et al. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. RMD Open 2020;6:e001145.
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rodevand E, et al. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford) 2012;51:1479–83.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065–71.
   PubMed Web of Science ®Google Scholar
• Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the Central Sensitization Inventory. Pain Pract 2012;12:276–85.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, et al. Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187–93.
   PubMed Web of Science ®Google Scholar
• Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.
   PubMed Web of Science ®Google Scholar
• Kregel J, Vuijk PJ, Descheemaeker F, Keizer D, van der Noord R, Nijs J, et al. The dutch Central Sensitization Inventory (CSI): factor analysis, discriminative power, and test-retest reliability. Clin J Pain 2016;32:624–30.
   PubMed Web of Science ®Google Scholar
• Neblett R, Cohen H, Choi Y, Hartzell MM, Williams M, Mayer TG, et al. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain 2013;14:438–45.
   PubMed Web of Science ®Google Scholar
• Ortolan A, Navarro-Compan V, Sepriano A, Landewe RBM, van der Heijde D, Ramiro S. Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. Rheumatology (Oxford) 2020;59:3990–2.
   PubMed Web of Science ®Google Scholar
• Baraliakos XTS, Gkelaki M, Dukatz P, Kiltz U, Braun J. Performance of standardized scores for disease assessment and pain in patients with spondyloarthritis and fibromyalgia [abstract]. Arthritis Rheumatol 2021;73 (suppl 9).
   PubMedGoogle Scholar
• Alunno A, Carubbi F, Stones S, Gerli R, Giacomelli R, Baraliakos X. The impact of Fibromyalgia in spondyloarthritis: from classification criteria to outcome measures. Front Med (Lausanne) 2018;5:290.
   PubMed Web of Science ®Google Scholar
• Kieskamp SC, Paap D, Carbo MJG, Wink F, Bos R, Bootsma H, et al. Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. Rheumatology (Oxford) 2021;60:4476–85.
   PubMed Web of Science ®Google Scholar
• Rusman T, van Bentum RE, van der Horst-Bruinsma IE. Sex and gender differences in axial spondyloarthritis: myths and truths. Rheumatology (Oxford) 2020;59:iv38–iv46.
   PubMed Web of Science ®Google Scholar
• Maguire S, Wilson F, Gallagher P, O’Shea FD. Worse scores but similar patterns of disease activity: interpreting outcomes in women with axial spondyloarthropathy. Scand J Rheumatol 2023;52:142–9.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe RB, Braun J, Baraliakos X, Hermann KG, Hsu B, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71:2002–5.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors. Ann Rheum Dis 2011;70:1375–81.
   PubMed Web of Science ®Google Scholar
• Ortolan A, Ramiro S, van Gaalen F, Kvien TK, Landewe RBM, Machado PM, et al. Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. Rheumatology (Oxford) 2021;60:638–48.
   PubMed Web of Science ®Google Scholar
• Ortolan A, Ramiro S, Ramonda R, van der Heijde D. External validation of the alternative ankylosing spondylitis disease activity score in three randomised clinical trials of ixekizumab. Rheumatology (Oxford) 2022 Oct 25:keac618.
   Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82:19–34.
   PubMed Web of Science ®Google Scholar